Japan’s recent Upper House election delivered a stinging defeat for the ruling Liberal Democratic Party (LDP) and junior coalition partner…
BUSINESS
Takeda’s Entyvio SC Form Hits Main Goal in PIII Crohn’s Disease Study
A subcutaneous formulation of Takeda Pharmaceutical’s inflammatory bowel disease treatment Entyvio (vedolizumab) achieved the primary endpoint in a global PIII study gauging it as a maintenance therapy for moderately to severely active Crohn’s disease (CD), according to the latest data.…
To read the full story
Related Article
- Takeda’s Entyvio SC Form Approved in Europe
May 11, 2020
- FDA Nixes Takeda’s Subcutaneous Entyvio Formulation
December 24, 2019
- Takeda Seeks Japan Approval for Entyvio SC Form
August 9, 2019
- Entyvio’s SC Form Accepted by US FDA for Review: Takeda
May 13, 2019
- Entyvio SC Form Now under EMA Review: Takeda
April 2, 2019
- Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda
July 20, 2018
BUSINESS
- Takeda Taps AI Demand Forecasting for 70% of Products, Aims to Bolster Supply Reliability
August 6, 2025
- Sumitomo Files iPS Cell-Derived Dopaminergic Progenitor Cells in Japan
August 6, 2025
- Japan Approves Updated Spikevax for LP.8.1 Omicron Strain
August 6, 2025
- FRONTEO Showcases Pharma Use Cases for AI Engine, Early Toxicity Prediction Possible
August 6, 2025
- ASKA, Kyorin End Partnership on BPH Drug AKP-009
August 5, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…